Anticoagulants and Hair Transplant Surgery: A Working Protocol

Surgical candidates have aged with the market. Men in their late fifties and sixties now book follicular unit excision alongside patients half their age, and the anticoagulants hair transplant teams once saw a few times a year now appear on intake forms weekly: apixaban for atrial fibrillation, clopidogrel after a coronary stent, warfarin for a mechanical valve, and aspirin bought without any prescriber involved at all. Many clinics still respond with the same reflex — stop everything seven days out. That reflex is the most dangerous instruction in elective aesthetic practice, because it treats capillary ooze in a compressible surgical field as though it outranked stroke, stent thrombosis and pulmonary embolism.

What follows is a working protocol: which agent classes matter, who owns each pause-or-continue decision, how the triage timeline runs from booking to theatre morning, and what changes technically when the correct plan is to operate while the medication continues. The organising principle does not bend. The clinic manages bleeding; only the prescriber manages clotting. Bleeding risk management is the clinic's half of the bargain, and it is the smaller half.

The risk asymmetry most clinics get backwards#

Scalp surgery sits at the favourable end of the bleeding spectrum. The field is superficial, there is no cavity to fill, and every bleeding point is visible and compressible. The worst plausible haemorrhagic outcome of continuing a single agent through FUE is a slow field, petechial bruising and prolonged crusting; a clinically significant haematoma is rare and manageable. The worst plausible outcome of an unnecessary pause is an arterial thrombosis in a patient who carried that risk for a cosmetic procedure. Those harms are not the same order of magnitude, and a protocol built as though they were is built backwards.

Cutaneous surgery worked through this asymmetry years ago: for minor dermatological procedures, continuing warfarin and secondary-prevention aspirin has become the default position, with interruption reserved for operations carrying genuine haemorrhagic stakes that scalp work does not resemble. Hair restoration inherits the reasoning almost unchanged. None of it, however, licenses the clinic to make the call. The point is narrower — the clinic should never be the party demanding interruption for its own convenience, because the party demanding interruption owns a share of whatever the interruption causes.

Anticoagulants hair transplant clinics must never pause on their own authority#

Patients say blood thinners; surgery planning needs pharmacology, because an antiplatelet, a vitamin K antagonist and a direct oral anticoagulant fail differently and recover on different clocks. Aspirin inhibits platelets for their circulating lifespan of seven to ten days; warfarin's effect drifts over days and is measurable as an INR; most DOACs clear within a day or two of a held dose, faster or slower with renal function. Those differences shape the questions. They do not shift the ownership, and every row of the table below carries the same footnote: the right-hand column describes what wider practice commonly does, and the decision belongs to the prescriber.

Two rows deserve emphasis. Dual antiplatelet therapy after recent stenting is not a negotiation: elective scalp surgery waits, and the cardiologist defines when the window opens. Bridging regimens signal a thrombotic risk profile — mechanical valves, recent venous thromboembolism — that belongs in a hospital-adjacent conversation rather than an outpatient aesthetic diary. Aspirin, meanwhile, is where triage most often fails in both directions: cardiac aspirin paused casually by the clinic, and self-directed aspirin continued because nobody asked about it.

Triage from booking to theatre morning#

The protocol runs on three timestamps. At booking, the coordinator screens the medication history against a named-drug checklist covering the anticoagulants hair transplant candidates most commonly take — apixaban, rivaroxaban, edoxaban, dabigatran, warfarin, clopidogrel, ticagrelor, prasugrel, aspirin — plus the supplement list, because a generic question about blood thinners reliably misses half of them. This screen is exactly the structured intake work described in our review of the patient coordinator role, and its output decides whether prescriber correspondence must precede a confirmed surgery date.

Ten to fourteen days out, the prescriber's written plan goes into the record: continue, pause for a specified number of days, or defer the case. If the plan says continue, consent wording expands to cover prolonged oozing, petechial bruising, extended crusting and a small residual haematoma risk. For warfarin patients, an INR is drawn within 24–72 hours of theatre. Cut-offs commonly used across cutaneous surgery sit in the upper therapeutic range, with many teams declining beyond roughly 3.0–3.5; these are conventions rather than guidelines, and the threshold a clinic adopts should be agreed with the anticoagulation service in advance, then written into the clinic's standard operating procedures.

On the morning itself, the checklist confirms that nothing has changed — the patient took, or held, exactly what the plan specified, and nobody improvised. International patients compress this timeline dangerously: a candidate landing on Sunday for Monday surgery has no slack for a supratherapeutic INR, so the written plan and any required blood work must exist before flights are booked, with the INR repeated locally on arrival.

Operating on the wet field#

When the plan says continue, the anticoagulants hair transplant patients arrive on call for technique, not heroics. Tumescence does most of the work: adrenaline concentrations in the 1:100,000 to 1:400,000 range produce a workable field in almost every anticoagulated patient, provided the team waits the full ten to fifteen minutes for vasoconstriction instead of punching into a freshly infiltrated donor. Extraction then proceeds in smaller zones with immediate gauze pressure along the harvest path. Punch selection does not change; bleeding is a field-management problem, not a geometry problem.

Recipient work rewards incision discipline. Narrow, depth-controlled channels ooze less than generous ones, and that discipline matters considerably more than blade material — the sapphire versus steel debate is close to irrelevant for haemostasis. Placement is where the field fights back: expect more graft popping, counter it with head elevation of twenty to thirty degrees and a calmer rhythm, and favour implanters where the team is fluent with them, because shorter open-site time suits a wet field.

The final discipline is time. A wet field slows placement, and slow placement stretches out-of-body intervals, so storage temperature, graft hydration and batch sizing need active management rather than habit.

What the evidence does and does not say#

There is no controlled evidence that a competently managed single agent reduces graft survival, and invoking survival to justify a pause is not an honest use of the literature. What the survival literature does support is indirect risk: the factors that measurably harm grafts are desiccation, temperature stress, mechanical trauma and prolonged out-of-body time — precisely the variables a slow, oozing case puts under pressure. Keeping out-of-body time inside the conventional four-hour ceiling, and preferably well under it, does more for graft survival than anything happening in the patient's plasma. Managed calmly, the wet case grows like any other; managed with irritation and haste, it fails through handling, and the medication takes the blame.

Decline, defer, proceed — the protocol's teeth#

A protocol without refusal criteria is a leaflet. The defensible hard stops: dual antiplatelet therapy inside the cardiologist's protected window; a morning-of INR above the pre-agreed threshold; a patient who paused or stopped medication on their own initiative, which means they are carrying a thrombotic risk nobody assessed; and any case where the prescriber declines to engage, which converts a surgical candidate into a correspondence file. Each of these is a deferral — documented, explained and rebookable — not a rejection.

Schedule pressure is the honest enemy. Per the 2025 ISHRS Practice Census, ISHRS members performed an average of 15 hair restoration surgeries per member per month in 2024, and a booked theatre slot exerts real gravitational pull on clinical judgement. Writing the deferral criteria into the SOP, and paying the team its day rate when a case stands down, removes the incentive to talk a borderline INR into theatre. Over a career, the clinic that never pauses an anticoagulant on its own authority accepts wetter fields and slower afternoons, and in exchange never has to explain why an elective cosmetic procedure justified a drug holiday that ended in a stroke. That is the trade, and it is a good one.

Sources and further reading#

• Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery. 2010;3(2):69–75.
• International Society of Hair Restoration Surgery (ISHRS) — professional society, training standards and practice census.